MDT - Medtronic
81.03
| Index: | S&P 500 | P/E: | 24.73 | EPS (ttm): | 3.28 | Insider Own: | 0.07% | Shs Outstand: | 1.28B | Perf Week: | -1.76% |
| Market Cap: | 105.25B | Forward P/E: | 13.87 | EPS next Y: | 5.84 | Insider Trans: | 0.00% | Shs Float: | 1.28B | Perf Month: | -3.66% |
| Income(ttm): | 4.29B | PEG: | 4.30 | EPS next Q: | 1.36 | Inst Own: | 84.63% | Short Float: | 0.78% | Perf Quarter: | -9.83% |
| Revenue(ttm): | 33.00B | P/S: | 3.19 | EPS this Y: | 4.81% | Inst Trans: | -0.88% | Short Ratio: | 1.65 | Perf Half Y: | -0.01% |
| Book/sh: | 37.81 | P/B: | 2.14 | EPS next Y: | 7.17% | ROA: | 4.76% | Short Interest: | 10.01M | Perf Year: | 0.52% |
| Cash/sh: | 6.15 | P/C: | 13.17 | EPS next 5Y: | 5.75% | ROE: | 8.58% | 52W Range: | 75.96 - 92.68 | Perf YTD: | -1.64% |
| Dividend Est.: | 2.71 (3.35%) | P/FCF: | 19.14 | EPS past 5Y: | -4.12% | ROI: | 5.87% | 52W High: | -12.57% | Beta: | 0.84 |
| Dividend TTM: | 2.09 (2.58%) | Quick Ratio: | 1.39 | Sales past 5Y: | 1.24% | Gross Margin: | 60.08% | 52W Low: | 6.67% | ATR (14): | 1.33 |
| Dividend Ex-Date: | Dec 27, 2024 | Current Ratio: | 1.84 | EPS Y/Y TTM: | 6.56% | Oper. Margin: | 17.93% | RSI (14): | 30.83 | Volatility: | 1.79% 1.50% |
| Employees: | 95000 | Debt/Eq: | 0.58 | Sales Y/Y TTM: | 3.25% | Profit Margin: | 13.00% | Recom: | 2.32 | Target Price: | 94.54 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.51 | EPS Q/Q: | 44.60% | Payout: | 99.87% | Rel Volume: | 1.77 | Prev Close: | 79.99 |
| Sales Surprise: | 1.55% | EPS Surprise: | 0.83% | Sales Q/Q: | 5.25% | Earnings: | Nov 19 BMO | Avg Volume: | 6.06M | Price: | 81.03 |
| SMA20: | -3.28% | SMA50: | -6.82% | SMA200: | -3.95% | Undervalued: 16.67% | Volume: | 10,706,627 | Change: | 1.30% | |
Graham Classic formula value: 58.91
(P/E=8 * 1g) Min value: 40.5
(current P/E * 2g) Max value: 106.71
Average value: 68.71
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.